Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts

Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

(2023) Stacey B. Armstrong et al.   MILITARY PSYCHOLOGY

105. Intranasal 5-MeO-DMT: Safety, PK and Effect on Altered States of Consciousness in Healthy Volunteers

(2023) James Rucker et al.   BIOLOGICAL PSYCHIATRY

US could soon approve MDMA therapy — opening an era of psychedelic medicine

(2023) Sara Reardon   NATURE

Efficacy of combined subanesthetic ketamine infusion and cervical sympathetic blockade as a symptomatic treatment of PTSD/TBI in a special forces patient with a 1-year follow-up: A case report

(2023) Eugene Lipov et al.   Heliyon

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

(2023) Stephanie Knatz Peck et al.   NATURE MEDICINE

Therapeutic mechanisms of psychedelics and entactogens

(2023) Boris D. Heifets et al.   NEUROPSYCHOPHARMACOLOGY

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico

(2023) Alan Kooi Davis et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

(2022) Meryem Grabski et al.   AMERICAN JOURNAL OF PSYCHIATRY

Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)‐ketamine on Symptoms of Treatment‐Resistant Depression and PTSD in Veterans: a Retrospective Case Series

(2022) S. Bentley et al.   PHARMACOTHERAPY

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

(2022) Guy M. Goodwin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psychedelic Drug Legislative Reform and Legalization in the US

(2022) Joshua S. Siegel et al.   JAMA Psychiatry

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open‐label observational study

(2021) T. Knuijver et al.   ADDICTION

Trial of Psilocybin versus Escitalopram for Depression

(2021) Robin Carhart-Harris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health Conditions Among Special Operations Forces Versus Conventional Military Service Members

(2021) Amanda Garcia et al.   JOURNAL OF HEAD TRAUMA REHABILITATION

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

(2019) Michael C. Mithoefer et al.   PSYCHOPHARMACOLOGY

Associations of Lifetime Traumatic Brain Injury Characteristics With Prospective Suicide Attempt Among Deployed US Army Soldiers

(2019) Laura Campbell-Sills et al.   JOURNAL OF HEAD TRAUMA REHABILITATION

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

(2019) Allison A. Feduccia et al.   Frontiers in Psychiatry

Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder

(2018) Sheila A. M. Rauch et al.   JAMA Psychiatry

How toxic is ibogaine?

(2016) Ruud P. W. Litjens et al.   CLINICAL TOXICOLOGY

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology

(2016) Ido Hartogsohn   JOURNAL OF PSYCHOPHARMACOLOGY

Effectiveness of National Implementation of Prolonged Exposure Therapy in Veterans Affairs Care

(2013) Afsoon Eftekhari et al.   JAMA Psychiatry